Abstract:Here we report previously unknown mechanism of the response of human primary, skin‐derived, keratinocytes (KCs) to proinflammatory insults. We found that the Nuclear Transport Checkpoint Inhibitor (NTCI), our Investigational New Drug, arrested the nuclear import of STAT3, the transcription factor involved in allergic inflammation, and the NF‐kappa B, prototypical proinflammatory Stress‐Responsive Transcription Factor, in human KCs. Among the genes and cognate proteins suppressed by the NTCI, was the major driver of allergic reactions, Thymic Stromal Lymphopoietin (TSLP), that promotes Th2 response. Moreover, other core proinflammatory mediators, TNF alpha, IL1 beta, IL6, IL8 and CSF2, were also suppressed in human KCs, thereby blocking the pathogenesis of AD and other dermatoses. Background In the two common inflammatory skin diseases, Atopic Dermatitis (AD) and Psoriasis (Ps), keratinocytes (KCs) respond to immune insults through activation of proinflammatory transcription factors (TFs) and their translocation to the cell's nucleus. Therein, the TFs induce expression of genes encoding mediators of skin inflammation. The Nuclear Transport Checkpoint Inhibitors (NTCIs) were developed to regulate nuclear translocation of activated TFs, the essential step of inflammatory response. This new class of cell‐penetrating peptide therapeutics controls inflammation caused by allergic, autoimmune, metabolic, and microbial insults. In preclinical model of AD, the treatment with NTCI, cSN50.1 peptide, suppressed the expression of Thymic Stromal Lymphopoietin (TSLP), the key gene in the development of allergic inflammation, among the 15 genes silenced by the NTCI. Here, we report the mechanism of anti‐inflammatory action of NTCI in human skin‐derived KCs. Objectives We aimed to determine whether the NTCI treatment can protect human KCs from harmful inflammatory insults. Methods Human primary KCs were pretreated with NTCI and challenged with the mix of cytokines Tumour Necrosis Factor alpha (TNF‐α) and Interleukin (IL)‐17A, or with Phorbol 12‐Myristate 13‐Acetate (PMA), and analysed for nuclear content of TFs and the expression of genes encoding mediators of inflammation. Results The nuclear import of TFs, Nuclear Factor ĸB (NF‐ĸB) and Signal Transduction and Activator of Transcription 3 (STAT3), was inhibited in cells treated with NTCI. The expression of TSLP, along with genes encoding the core mediators of inflammation (TNF, IL1B, and IL6) was suppressed by NTCI. Noteworthy, NTCI silenced genes encoding Granulocyte‐Macrophage Colony‐Stimulating Factor (CSF2), and chemokine IL‐8 (CXCL8), responsible for skin infiltration by the eosinophils and other myelomonocytic cells. Conclusion The control of inflammatory response in human KCs by NTCI is attributed to the inhibition of nuclear import of proinflammatory TFs. The protection of human KCs by NTCI, adds new perspectives to the completed Phase two clinical trial of the NTCI (AMTX‐100 CF) for AD (NCT04313400).

[Expression of Nuclear Factor Kappab and the Effect of Topical Tacrolimus Ointment on Lesional Atopic Dermatitis Skin].

[Effect of Topical Tacrolimus Ointment on Expression of Toll-like Receptors 2 and 4 in Lesional Atopic Dermatitis Skin].

Expression of HSP70 and the effect of topical tacrolimus on the expression in skin lesions of atopic dermatitis

Effects of Antioxidants and Nitric Oxide on TNF-α-induced Adhesion Molecule Expression and NF-κB Activation in Human Dermal Microvascular Endothelial Cells

Topical Application of FK506 (Tacrolimus) Ointment Inhibits Mite Antigen-Induced Dermatitis by Local Action in NC/Nga Mice

Genomic control of inflammation in experimental atopic dermatitis

Differences in therapeutic effects of topically applied corticosteroid and tacrolimus on atopic dermatitis-like symptoms in NC/Nga mice

Effects of Tacrolimus on the Expression of Proteinase Activated Receptor 2 in Lesions of Atopic Dermatitis

Evaluation the Effect of Phytosterol Fraction of Chenopodium Murale in Comparison with Tacrolimus on Mice Induced Atopic Dermatitis

Efficacy and Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis in Chinese Children

Fucoxanthin Ameliorates Atopic Dermatitis Symptoms by Regulating Keratinocytes and Regulatory Innate Lymphoid Cells

Effect of Physiological Changes in the Skin on Systemic Absorption of Tacrolimus Following Topical Application in Rats

Anti‐inflammatory control of human skin keratinocytes by targeting nuclear transport checkpoint

Efficacy and Safety of Tacrolimus Ointment in Treatment of Atopic Dermatitis of Child and Adult in 51 Patients

Skin and systemic inflammation in adults with atopic dermatitis before and after whole-body topical betamethasone 17-valerate 0.1% or tacrolimus 0.1% treatment: A randomized controlled study

Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis

Effect and mechanism of tacrolimus on melanogenesis on A375 human melanoma cells

Topical tacrolimus suppresses the expression of vascular endothelial growth factor and insulin-like growth factor-1 in late anagen.

Topical therapy of atopic dermatitis with a focus on pimecrolimus

Intermittent or Sequential Topical Tacrolimus in Atopic Dermatitis: Systematic Review and Meta-Analysis

Topical Tetracycline Improves MC903-induced Atopic Dermatitis in Mice through Inhibition of Inflammatory Cytokines and Thymic Stromal Lymphopoietin Expression.